Technology Offerings

Inventors of Saarland University achieved to develop new neutral bis azainositol heavy metal complexes suitable for the use as X-ray contrast agents with a wide range of advantages compared to common contrast agents. For their higher absorption coefficient in the range of voltages used in CT these complexes lead to scan protocols that provide equivalent or even improved diagnostic value at lower radiation doses compared to conventional triiodinated contrast agents.

Sensitive sensors and other electronic and optoelectronic components require reliable capsulations, which withstand long-lasting environmental difficulty. Such housings, with grommets for electrical connections in surroundings with low air or rather gas pressure and in the vacuum technology, require particularly high standards.

The presented innovation is a new method for head measurement which works with an app. Scopes of application of the new method can be found in the field of diagnosis and treatment of cranial deformations, e.g. the helmet therapy.

Among Gram-positive bacteria are some of the most dangerous pathogens for humans. Especially Methicillin-resistant Staphylococcus aureus (MRSA) is responsible for a high percentage of hospital-acquired and deadly infections.
We have identified a naturally human-associated bacterial antibiotic producer strain (S. lugdunensis IVK28 wild type), which may act as a probiotic cure before patients enter hospital. Its application could avoid costly decolonization of human commensal bacteria before surgery.
From this bacterium we furthermore isolated a previously unknown class of peptide related structures with high potential as new antibiotics. Total chemical synthesis has been established.
The main compound Lugdunin shows very high potential against MRSA and other highly-resistant species like Enterococcus faecalis, E. faecium (VRE), Streptococcus pneumoniae and Listeria monocytogenes.
A patent application covering the chemical structures, the genetic background of the producer strain and the bioactivity of the new substances has been filed.

More than 90% of drugs passing through today's preclinical cell cultures studies fail to meet the desired efficacy or safety. Tissue engineering has undergone exciting progress and more similar to the in vivo situation. Scientists at University of Göttingen developed a new device for automated tissue engineering & drug testing.

We offer a electromyogramm (EMG) electrode for the chronic percutaneous implantation for a robust and reliable electromyogram detection in myolectric control of e.g. prosthesis. It solves reliability issues related to skin conditions, electrode lift-offs and variations of electrode positioning. No wireless transmission is needed, they can be directly connected external amplifiers.